

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Xalkori (crizotinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Xalkori (crizotinib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Xalkori (crizotinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Non-small cell lung cancer (NSCLC), recurrent or metastatic; **AND**
- II. There is confirmation that the tumor is:
 - A. Anaplastic lymphoma kinase (ALK)-positive; **OR**
 - B. C-ros oncogene 1(ROS1) positive; **OR**
 - C. Mesenchymal-Epidermal Transition (MET) amplifications are present (NCCN 2A); **OR**
 - D. Inflammatory Myofibroblastic Tumor (IMT) with ALK translocation (NCCN 2A);

OR

- III. Individual has a diagnosis of Central Nervous System Cancers; **AND**
- IV. Individual has recurrent disease for brain metastases if active against the primary tumor (NSCLC) (NCCN 2A);

OR

- V. Individual has a diagnosis of Soft Tissue Sarcoma; **AND**
- VI. Individual is using as monotherapy for Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation (NCCN 2A);

OR

- VII. Individual has a diagnosis of Peripheral T-cell Lymphomas; **AND**
- VIII. Individual is using as monotherapy for relapsed/refractory ALK-positive anaplastic large cell lymphoma (NCCN 2A).

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.